Related Experiment Videos
Iron chelator research: past, present, and future.
Tim F Tam1, Regis Leung-Toung, Wanren Li
1Medicinal Chemistry Department, Apotex Research, Inc., 400 Ormont Drive, Toronto, Ontario, Canada. ttam@apotex.com
Current Medicinal Chemistry
|April 8, 2003
Summary
Iron chelators treat iron overload in beta-thalassemia. New chelators are being developed for other diseases, including cancer, viral infections, and fibrotic conditions.
Area of Science:
- Biochemistry
- Pharmacology
- Hematology
Background:
- In vivo iron toxicity presents as iron overload (e.g., beta-thalassemia, hereditary hemochromatosis) or iron-dependent non-overload conditions (e.g., anthracycline cardiotoxicity).
- Numerous iron chelators exist, but few have undergone human trials, with desferrioxamine (DFO), deferiprone (L1), and dexrazoxane (ICRF 187) being notable examples.
Purpose of the Study:
- To review the drug development status of iron chelators for beta-thalassemia iron overload.
- To explore emerging applications of iron chelators in treating or preventing other diseases.
Main Methods:
- Literature review of iron chelator development and clinical trials.
- Analysis of preclinical and clinical data for novel iron chelating agents.
- Examination of recent reports on expanded utilities of iron chelators.
Main Results:
- Several iron chelators are in various stages of development, including ICL670 (Phase III planned), Triapine (Phase II), and new agents like CP502, GT56-252, NaHBED, and MPB0201.
- Iron chelators show promise beyond iron overload, with reported applications as antiviral, photoprotective, antiproliferative, and antifibrotic agents.
Conclusions:
- Significant progress is being made in developing iron chelators for beta-thalassemia.
- Iron chelators represent a versatile therapeutic class with potential applications in a wide range of diseases beyond iron overload conditions.